RIME Therapeutics receives the AbbVie Biotech Innovators Award to support innovative drug discovery in inflammation and immunology.
Quiver AI Summary
AbbVie, in partnership with adMare BioInnovations, has awarded the AbbVie Biotech Innovators Award to Montreal-based start-up RIME Therapeutics, which focuses on peptide-based drug discovery for inflammation and immunology. This award provides RIME with a year of laboratory and office space at the adMare Innovation Centre, including shared access to equipment and mentorship from AbbVie's leaders. RIME Therapeutics aims to bridge the gap in drug discovery with its innovative Disruptide Platform, which integrates various scientific disciplines for improving therapy development. Both AbbVie and adMare emphasize the importance of supporting early-stage biotech innovation in Canada to foster growth in the life sciences sector and address pressing health challenges.
Potential Positives
- AbbVie showcases its commitment to fostering innovation in Quebec's life sciences sector through the AbbVie Biotech Innovators Award, supporting early-stage biotech companies.
- The award provides RIME Therapeutics with valuable resources, including a year of laboratory and office space, shared equipment, and mentorship from AbbVie’s leaders, enhancing its potential for successful drug development.
- This initiative aligns with AbbVie's strategic focus on therapeutic areas such as immunology, showcasing the company's support for innovations that may lead to transformational therapies in these fields.
Potential Negatives
- AbbVie’s emphasis on supporting external biotech companies like RIME Therapeutics may indicate internal challenges in developing its innovation pipeline independently, raising concerns about its own research capabilities.
- The press release does not provide any specific information about successful past collaborations, which may lead to skepticism about the long-term impact of the AbbVie Biotech Innovators Award on the biotech ecosystem.
- The reliance on external awards and partnerships to promote innovation could suggest that AbbVie is not fully confident in its own biotechnology development efforts, potentially affecting investor confidence.
FAQ
What is the AbbVie Biotech Innovators Award?
The award supports early-stage biotechnology companies in Quebec, helping them develop transformative therapies in key therapeutic areas.
Who won the AbbVie Biotech Innovators Award in 2026?
RIME Therapeutics, a Montreal-based start-up focused on drug discovery, received the award to accelerate its research efforts.
What benefits does RIME Therapeutics receive from the award?
RIME Therapeutics will gain access to laboratory and office space, shared equipment, and mentorship from AbbVie’s leaders for one year.
How does RIME Therapeutics contribute to immunology research?
The company employs a unique peptide-based drug discovery platform aimed at identifying targets and accelerating therapies for inflammation and immunology.
Why is AbbVie focused on supporting biotech innovation in Canada?
AbbVie aims to foster a thriving life sciences ecosystem and accelerate scientific innovations to address pressing health challenges in Canada.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ABBV Insider Trading Activity
$ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
- DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$ABBV Revenue
$ABBV had revenues of $15B in Q1 2026. This is an increase of 12.43% from the same period in the prior year.
You can track ABBV financials on Quiver Quantitative's ABBV stock page.
$ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
$ABBV Hedge Fund Activity
We have seen 1,769 institutional investors add shares of $ABBV stock to their portfolio, and 1,868 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 37,400,173 shares (-74.3%) from their portfolio in Q4 2025, for an estimated $8,545,565,528
- CAPITAL WORLD INVESTORS added 6,736,161 shares (+106.3%) to their portfolio in Q4 2025, for an estimated $1,539,145,426
- BLACKROCK, INC. added 5,197,454 shares (+3.6%) to their portfolio in Q4 2025, for an estimated $1,187,566,264
- CARDANO RISK MANAGEMENT B.V. removed 4,908,260 shares (-90.1%) from their portfolio in Q1 2026, for an estimated $1,062,785,537
- WELLINGTON MANAGEMENT GROUP LLP added 4,389,782 shares (+41.7%) to their portfolio in Q4 2025, for an estimated $1,003,021,289
- GEODE CAPITAL MANAGEMENT, LLC added 4,190,487 shares (+10.4%) to their portfolio in Q4 2025, for an estimated $957,484,374
- JPMORGAN CHASE & CO removed 4,141,493 shares (-7.3%) from their portfolio in Q4 2025, for an estimated $946,289,735
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$ABBV Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HSBC issued a "Buy" rating on 12/10/2025
To track analyst ratings and price targets for $ABBV, check out Quiver Quantitative's $ABBV forecast page.
$ABBV Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 13 analysts offer price targets for $ABBV in the last 6 months, with a median target of $260.0.
Here are some recent targets:
- Carter Gould from Cantor Fitzgerald set a target price of $240.0 on 04/30/2026
- Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026
- David Amsellem from Piper Sandler set a target price of $294.0 on 04/23/2026
- Gary Nachman from Canaccord Genuity set a target price of $262.0 on 04/21/2026
- Vamil Divan from Guggenheim set a target price of $249.0 on 04/10/2026
- Trung Huynh from RBC Capital set a target price of $260.0 on 02/25/2026
- Emily Field from Barclays set a target price of $275.0 on 02/20/2026
Full Release
- National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.
- Award provides RIME Therapeutics with a year of laboratory and office space, including access to shared equipment and services at the adMare Innovation Centre in Montreal, as well as mentorship from AbbVie’s scientific and business leaders.
-
RIME Therapeutics to impact inflammation and immunology research and innovation.
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV), jointly with adMare BioInnovations, today recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, a prize designed to help foster innovation and support growth in Quebec’s life sciences sector.
Founded in 2025, RIME Therapeutics is a Montreal-based start-up focused on developing a peptide-based drug discovery platform designed to identify protein-protein interaction targets and accelerate the discovery of therapies for inflammation and immunology. The company impressed the selection committee with its function-first disruptive approach, merging target discovery with simultaneous hit identification, and designed to address novel T cell biology with broad therapeutic applicability.
An environment that values innovation is essential to foster growth in Canada’s life sciences sector. Enabling partnerships and offering the right infrastructure, mentorship and collaboration to support early-stage biotech entrepreneurs play a critical role in advancing the next generation of breakthrough therapies for people living with devastating diseases in Canada.
The AbbVie Biotech Innovators Award supports early-stage biotechnology companies with the potential to generate transformational therapies in areas that align with AbbVie’s therapeutic areas of focus, including immunology, oncology, neuroscience, and aesthetics. Funded by AbbVie, the award will provide RIME Therapeutics with one year of laboratory and office space at the adMare Innovation Centre in Montreal, including access to shared equipment and services. The company will also benefit from the expertise and mentorship of AbbVie's scientific and business leaders to help accelerate the advancement of its research.
"We are honoured to receive the AbbVie Biotech Innovators Award to further support our work at RIME," said Michael Mee, CEO at RIME Therapeutics and Managing Director of Pre-Amp, Amplitude Ventures’ company creation studio. "Our Disruptide Platform is built to solve one of drug discovery's most persistent challenges, bridging the gap between knowing what to drug and knowing how to drug it. With the support of AbbVie and adMare BioInnovations, we are accelerating our path from novel biology to tractable chemistry, moving towards a differentiated pipeline of medicines for patients."
"This award reflects our focus on helping create and scale globally competitive Canadian life sciences companies," said Matthew Carlyle, President and CEO of adMare BioInnovations. "We are pleased to partner with AbbVie to support promising biotech innovators by providing access to world-class infrastructure, expertise and mentorship so they can focus on advancing breakthrough discoveries, building value and scaling their business here in Canada."
"The AbbVie Biotech Innovators Award underscores AbbVie’s commitment to fostering a thriving life sciences ecosystem in Quebec and across Canada," said Stéphanie Sauvageau, Head of Medical, AbbVie Canada. "By supporting early-stage biotech companies like RIME Therapeutics, we aim to accelerate scientific innovation and advance solutions to some of the most pressing health challenges facing Canadians."
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Instagram or find us on LinkedIn .
About adMare BioInnovations
adMare BioInnovations is Canada’s life sciences company creation engine, focused on building and scaling strong, investable companies. Our unique model identifies breakthrough innovations addressing unmet patient needs and supports early company creation with early-stage capital, commercial R&D and IP and business development expertise. This approach helps establish the scientific validation, value, and operating foundations needed to build globally competitive Canadian life science companies. To date, adMare has helped create 39 companies that have attracted $2.5 billion in risk capital, achieved a combined value of $5.8 billion, and created approximately 1,000 jobs.
adMare also provides more than 200,000 square feet of turnkey lab facilities and delivers industry-ready talent and executive leadership development programs to help Canadian life science companies scale and succeed. Learn more at www.admarebio.com .
About RIME Therapeutics
RIME Therapeutics is a Montreal-based drug discovery company bridging the gap between target identification and chemical tractability using the company's function-first Disruptide Platform. Integrating human genetics, perturbation biology, and AI, RIME scans functional drug pocket space, simultaneously discovering and validating novel intracellular targets and delivering functional chemical hits against them, with the goal of building a differentiated pipeline of medicines. Follow us on LinkedIn @RIME Therapeutics or visit
rimetherapeutics.com
.
Media Inquiries:
| Dominique Touchette | Bethany Moir |
| Lead, Communications | Senior Director, Public Affairs |
| AbbVie | adMare BioInnovations |
| [email protected] | [email protected] |
